Exploring beta blocking as a possible mechanism of anticancer action of 2- thiohydantoins

Abstract

This study is a continuation of our previous work in which we examined the anticancer potential of a series of zingerone 2-thiohydantoin derivatives. Using molecular docking, we explored whether beta blocking is a possible mechanism of their anticancer action. Active and inactive derivatives were docked into the structure of the beta-2 adrenergic receptor and their preferred binding sites, binding affinities and interactions were compared and discussed. The results show a discernible difference in which the active and inactive derivatives interact with the receptor and indicate that beta blocking could be a possible mechanism of their anticancer action.